Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Immunology

Abstract 4733: Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T Cell Lymphomas .

Nicolas Viaud, Nathalie Granier, Stephanie Zerbib, Arnaud Dujardin, Cecile Bonnafous, Mathieu Blery, Carine Paturel, Benjamin Rossi, Anne Marie-Cardine, Armand Bensussan, Martine Bagot and Helene Sicard
Nicolas Viaud
1Innate Pharma, Marseille, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Granier
1Innate Pharma, Marseille, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Zerbib
1Innate Pharma, Marseille, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnaud Dujardin
1Innate Pharma, Marseille, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cecile Bonnafous
1Innate Pharma, Marseille, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathieu Blery
1Innate Pharma, Marseille, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carine Paturel
1Innate Pharma, Marseille, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Rossi
1Innate Pharma, Marseille, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Marie-Cardine
2INSERM U976, Hosp. Saint Louis, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Armand Bensussan
2INSERM U976, Hosp. Saint Louis, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martine Bagot
2INSERM U976, Hosp. Saint Louis, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helene Sicard
1Innate Pharma, Marseille, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2013-4733 Published April 2013
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC

Abstract

KIR3DL2 belongs to the killer immunoglobulin (Ig)-like receptors (KIRs) family and is composed of three extracellular Ig-like domains. KIR3DL2 is naturally expressed on some NK cells and minor subpopulations of CD8+ and CD4+ T cells. Physiologically, KIRD3L2 is an inhibitory receptor for human leukocyte antigen (HLA) class I molecules regulating NK cell activation. Remarkably, KIR3DL2 is also aberrantly overexpressed on several subtypes of T lymphomas/leukemias, such as Sezary Syndrome, transformed Mycosis Fungoides and HTLV1+ Adult T Cell Leukemia, making it a unique therapeutic target in cancer. We have generated a series of anti-KIR3DL2 monoclonal antibodies (mAbs) binding selectively to KIR3DL2, spanning epitopes on each of the three Ig domains. Their efficacy was evaluated in vitro and in vivo against KIR3DL2-expressing tumors and Sezary cell lines as disease model. Various modes of action, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC) were found involved in their anti-tumor activity. In parallel, anti-KIR3DL2 mAbs were also developed as unique and sensitive tools for the detection by immunohistochemistry of KIR3DL2 on tumor biopsies. Owing to the promising efficacy profile of our anti-KIR3DL2 mAb candidates and to the highly restricted expression pattern of the target on some T leukemia/lymphoma cells, an antibody-based therapy targeting KIR3DL2 stands as a potentially unequalled strategy in several orphan diseases with critical unmet medical need.

Citation Format: Nicolas Viaud, Nathalie Granier, Stephanie Zerbib, Arnaud Dujardin, Cecile Bonnafous, Mathieu Blery, Carine Paturel, Benjamin Rossi, Anne Marie-Cardine, Armand Bensussan, Martine Bagot, Helene Sicard. Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T Cell Lymphomas . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4733. doi:10.1158/1538-7445.AM2013-4733

  • ©2013 American Association for Cancer Research
Back to top
Cancer Research: 73 (8 Supplement)
April 2013
Volume 73, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 4733: Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T Cell Lymphomas .
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 4733: Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T Cell Lymphomas .
Nicolas Viaud, Nathalie Granier, Stephanie Zerbib, Arnaud Dujardin, Cecile Bonnafous, Mathieu Blery, Carine Paturel, Benjamin Rossi, Anne Marie-Cardine, Armand Bensussan, Martine Bagot and Helene Sicard
Cancer Res April 15 2013 (73) (8 Supplement) 4733; DOI: 10.1158/1538-7445.AM2013-4733

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 4733: Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T Cell Lymphomas .
Nicolas Viaud, Nathalie Granier, Stephanie Zerbib, Arnaud Dujardin, Cecile Bonnafous, Mathieu Blery, Carine Paturel, Benjamin Rossi, Anne Marie-Cardine, Armand Bensussan, Martine Bagot and Helene Sicard
Cancer Res April 15 2013 (73) (8 Supplement) 4733; DOI: 10.1158/1538-7445.AM2013-4733
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Immunology

  • Abstract SY03-03: Modulating innate and adaptive immunity through the manipulation of dendritic cells
  • Abstract SY03-02: Wnt signaling generates “stem-like” self-renewing T cells that can eradicate tumors
  • Abstract SY03-01: The desirable death of the cancer cell: Immunogenic cell death for optimal chemotherapy
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Immune Therapeutics and Monoclonal Antibodies 2

  • Abstract 4739: Effects of whole-body heat treatment on antigen specific T cells responses.
  • Abstract 4751: Simultaneous inhibition of EGFR, HER2 and HER3 by an antibody mixture provides broad and potent tumor inhibition.
  • Abstract 4740: Doxorubicin eliminates tumor-induced myeloid-derived suppressor cells and enhances T-helper lymphocyte-based immunotherapy in a murine breast cancer model.
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement